Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OCUL – Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.
OCUL
$9.22
Name : Ocular Therapeutix, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,468,745,984.00
EPSttm : -1.11
finviz dynamic chart for OCUL
Ocular Therapeutix, Inc.
$9.22
2.54%
$0.24

Float Short %

10.79

Margin Of Safety %

Put/Call OI Ratio

0.2

EPS Next Q Diff

0.02

EPS Last/This Y

-0.23

EPS This/Next Y

0.15

Price

9.23

Target Price

17.46

Analyst Recom

1.08

Performance Q

18.97

Relative Volume

2.03

Beta

1.43

Ticker: OCUL




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02OCUL8.120.180.3531725
2025-06-03OCUL8.340.180.0231620
2025-06-04OCUL8.380.170.0133890
2025-06-05OCUL8.460.170.0834259
2025-06-06OCUL9.020.170.0134281
2025-06-09OCUL8.90.170.0034620
2025-06-10OCUL8.910.240.0036703
2025-06-11OCUL8.820.240.0037032
2025-06-12OCUL8.950.240.0437138
2025-06-13OCUL8.730.240.5037339
2025-06-16OCUL8.750.240.4337344
2025-06-17OCUL8.290.240.0037364
2025-06-18OCUL8.320.240.0637418
2025-06-20OCUL8.090.240.0237526
2025-06-23OCUL8.380.200.0230543
2025-06-24OCUL9.10.200.0831304
2025-06-25OCUL9.190.200.1232378
2025-06-26OCUL9.460.190.0032949
2025-06-27OCUL9.220.200.7132763
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02OCUL8.12-36.5- -1.38
2025-06-03OCUL8.33-36.5- -1.38
2025-06-04OCUL8.37-36.5- -1.38
2025-06-05OCUL8.46-36.5- -1.38
2025-06-06OCUL9.03-36.5- -1.45
2025-06-09OCUL8.90-36.5- -1.45
2025-06-10OCUL8.93-36.5- -1.45
2025-06-11OCUL8.81-36.5- -1.45
2025-06-12OCUL8.95-36.5- -1.45
2025-06-13OCUL8.73-36.5- -1.45
2025-06-16OCUL8.74-36.5- -1.45
2025-06-17OCUL8.29-36.5- -1.45
2025-06-18OCUL8.33-36.5- -1.45
2025-06-20OCUL8.13-36.5- -1.45
2025-06-23OCUL8.39-36.5- -1.45
2025-06-24OCUL9.10-36.5- -1.45
2025-06-25OCUL9.19-36.5- -1.45
2025-06-26OCUL9.46-36.5- -1.45
2025-06-27OCUL9.23-36.5- -1.45
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02OCUL-0.263.5310.34
2025-06-03OCUL-0.313.5310.34
2025-06-04OCUL-0.313.5310.34
2025-06-05OCUL-0.313.5310.34
2025-06-06OCUL-0.313.5310.34
2025-06-09OCUL-0.313.5410.34
2025-06-10OCUL-0.313.5410.34
2025-06-11OCUL-0.313.5410.67
2025-06-12OCUL-0.313.5410.67
2025-06-13OCUL-0.313.5410.67
2025-06-16OCUL-0.313.5410.67
2025-06-18OCUL-0.313.5410.67
2025-06-20OCUL-0.313.5410.67
2025-06-23OCUL-0.313.5410.67
2025-06-24OCUL-0.313.5410.67
2025-06-25OCUL-0.313.5410.67
2025-06-26OCUL-0.313.5410.79
2025-06-27OCUL-0.313.5410.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.38

Avg. EPS Est. Current Quarter

-0.35

Avg. EPS Est. Next Quarter

-0.36

Insider Transactions

-0.31

Institutional Transactions

3.54

Beta

1.43

Average Sales Estimate Current Quarter

13

Average Sales Estimate Next Quarter

14

Fair Value

Quality Score

42

Growth Score

44

Sentiment Score

95

Actual DrawDown %

62

Max Drawdown 5-Year %

-90.9

Target Price

17.46

P/E

Forward P/E

PEG

P/S

24.62

P/B

5.52

P/Free Cash Flow

EPS

-1.15

Average EPS Est. Cur. Y​

-1.45

EPS Next Y. (Est.)

-1.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-323.09

Relative Volume

2.03

Return on Equity vs Sector %

-96.4

Return on Equity vs Industry %

-78.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.24

EBIT Estimation

Ocular Therapeutix, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 274
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today
news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance
stock history OCUL – Ocular Therapeutix, Inc. invest stock market
stock prices OCUL premarket after hours
ticker OCUL fair value insiders trading